Aspirate from human stented native coronary arteries vs. saphenous vein grafts: more endothelin but less particulate debris.

Stent implantation into atherosclerotic coronary arteries releases particulate debris and soluble substances that contribute to impaired microvascular perfusion. Here we addressed the potential for microvascular obstruction in patients with stenotic native right coronary arteries (nRCA) compared with saphenous vein grafts on right coronary arteries (SVG-RCA). We enrolled symptomatic, male patients with stable angina pectoris and a flow-limiting stenosis in their nRCA or SVG-RCA (n = 18/18). Plaque volume and composition were analyzed using intravascular ultrasound before stent implantation. Coronary aspirate was retrieved during stent implantation under protection with a distal occlusion/aspiration device and divided into particulate debris and plasma. The release of catecholamines, endothelin, serotonin, thromboxane B2, and tumor necrosis factor-α was measured. The response of rat mesenteric arteries with intact (+E) and denuded (-E) endothelium to aspirate plasma (without and with selective endothelin receptor blockade) was normalized to that by potassium chloride (KClmax = 100%). Plaque volume and composition were not different between nRCA and SVG-RCA. There was less particulate debris (65 ± 8 vs. 146 ± 23 mg; P < 0.05) and more endothelin release (5.8 ± 0.8 vs. 1.3 ± 0.7 pg/ml; P < 0.05) in nRCA than in SVG-RCA, whereas the release of the other mediators was not different. Aspirate from nRCA induced stronger vasoconstriction than that from SVG-RCA [nRCA, 78 ± 6% (+E)/84 ± 5% (-E); SVG-RCA, 59 ± 6% (+E)/68 ± 3% (-E); P < 0.05 nRCA vs. SVG-RCA], which was attenuated by a nonspecific endothelin and a specific endothelin receptor A antagonist. Thus coronary aspirate from stented nRCA is characterized by less debris but more endothelin and stronger vasoconstrictor response than that from SVG-RCA.

[1]  Fred S Apple,et al.  Third universal definition of myocardial infarction , 2012 .

[2]  S. Möhlenkamp,et al.  Saphenous vein aorto-coronary graft atherosclerosis in patients with chronic kidney disease: more plaque calcification and necrosis, but less vasoconstrictor potential , 2012, Basic Research in Cardiology.

[3]  R. Erbel,et al.  Lessons from human coronary aspirate. , 2012, Journal of molecular and cellular cardiology.

[4]  G. Levine,et al.  2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention. A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. , 2011, Journal of the American College of Cardiology.

[5]  S. Möhlenkamp,et al.  Acute vasomotor paralysis and potential downstream effects of paclitaxel from stents implanted for saphenous vein aorto-coronary bypass stenosis , 2011, Basic Research in Cardiology.

[6]  GerdHeusch,et al.  Vasoconstrictor Potential of Coronary Aspirate From Patients Undergoing Stenting of Saphenous Vein Aortocoronary Bypass Grafts and Its Pharmacological Attenuation , 2011 .

[7]  G. Heusch,et al.  TNFalpha in atherosclerosis, myocardial ischemia/reperfusion and heart failure. , 2010, Pharmacology & therapeutics.

[8]  S. Frisbee,et al.  Aspirin resistance with genetic dyslipidemia: contribution of vascular thromboxane generation. , 2010, Physiological genomics.

[9]  O. Muller,et al.  Relation of endothelial function to residual platelet reactivity after clopidogrel in patients with stable angina pectoris undergoing percutaneous coronary intervention. , 2010, The American journal of cardiology.

[10]  R. Erbel,et al.  Coronary microembolization: from bedside to bench and back to bedside. , 2009, Circulation.

[11]  W. J. van der Giessen,et al.  Functional and Structural Adaptations of Coronary Microvessels Distal to a Chronic Coronary Artery Stenosis , 2008, Circulation research.

[12]  K. Werdan,et al.  Invited review: Vascular cells contribute to atherosclerosis by cytokine- and innate-immunity-related inflammatory mechanisms , 2008, Innate immunity.

[13]  R. Virmani,et al.  Long-term histological and immunohistochemical findings in human venous aorto-coronary bypass grafts. , 2008, Clinical science.

[14]  J. Ormiston,et al.  Distal embolization during native vessel and vein graft coronary intervention with a vascular protection device: predictors of high-risk lesions. , 2007, Journal of interventional cardiology.

[15]  A. Feldman,et al.  TNF-&agr; Contributes to Endothelial Dysfunction by Upregulating Arginase in Ischemia/Reperfusion Injury , 2007 .

[16]  G. Maurer,et al.  Active endothelin is an important vasoconstrictor in acute coronary thrombi , 2007, Thrombosis and Haemostasis.

[17]  A. Feldman,et al.  TNF-alpha contributes to endothelial dysfunction by upregulating arginase in ischemia/reperfusion injury. , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[18]  E. Romagnoli,et al.  Endothelin-1 and acute myocardial infarction: a no-reflow mediator after successful percutaneous myocardial revascularization. , 2006, European heart journal.

[19]  R. Erbel,et al.  Intense vasoconstriction in response to aspirate from stented saphenous vein aortocoronary bypass grafts. , 2006, Journal of the American College of Cardiology.

[20]  A. Jacobs,et al.  Aspirin resistance and atherothrombotic disease. , 2005, Journal of the American College of Cardiology.

[21]  N. Weissman,et al.  Incidence and clinical correlates of ruptured plaques in saphenous vein grafts: an intravascular ultrasound study. , 2005, Journal of the American College of Cardiology.

[22]  W. Chilian,et al.  Cardiac myocytes control release of endothelin-1 in coronary vasculature. , 2005, American journal of physiology. Heart and circulatory physiology.

[23]  白井 伸幸 Expression of endothelin-converting enzyme, endothelin-1 and endothelin receptors at the site of percutaneous coronary intervention in humans , 2005 .

[24]  K. Kent,et al.  Effect of direct stenting on clinical outcome in patients treated with percutaneous coronary intervention on saphenous vein graft. , 2003, American heart journal.

[25]  G. Stone,et al.  Randomized Comparison of Distal Protection With a Filter-Based Catheter and a Balloon Occlusion and Aspiration System During Percutaneous Intervention of Diseased Saphenous Vein Aorto-Coronary Bypass Grafts , 2003, Circulation.

[26]  G. Maurer,et al.  Coronary no-reflow is caused by shedding of active tissue factor from dissected atherosclerotic plaque. , 2002, Blood.

[27]  M. Leon,et al.  Randomized Trial of a Distal Embolic Protection Device During Percutaneous Intervention of Saphenous Vein Aorto-Coronary Bypass Grafts , 2002, Circulation.

[28]  A. Yeung,et al.  Prevention of Distal Embolization During Coronary Angioplasty in Saphenous Vein Grafts and Native Vessels Using Porous Filter Protection , 2001, Circulation.

[29]  F. Cipollone,et al.  Overexpression of Functionally Coupled Cyclooxygenase-2 and Prostaglandin E Synthase in Symptomatic Atherosclerotic Plaques as a Basis of Prostaglandin E2-Dependent Plaque Instability , 2001, Circulation.

[30]  C. Tracy,et al.  American College of Cardiology Clinical Expert Consensus Document on Standards for Acquisition, Measurement and Reporting of Intravascular Ultrasound Studies (IVUS). A report of the American College of Cardiology Task Force on Clinical Expert Consensus Documents. , 2001, Journal of the American College of Cardiology.

[31]  T. Lüscher,et al.  Endothelins and Endothelin Receptor Antagonists: Therapeutic Considerations for a Novel Class of Cardiovascular Drugs , 2000, Circulation.

[32]  G. Caughey,et al.  Differential Regulation of Prostaglandin E2 and Thromboxane A2 Production in Human Monocytes: Implications for the Use of Cyclooxygenase Inhibitors1 , 2000, The Journal of Immunology.

[33]  F. Schaefer,et al.  ANG II- and TxA2-induced mesenteric vasoconstriction in rats is mediated by separate cell signaling pathways. , 1999, American journal of physiology. Heart and circulatory physiology.

[34]  T. Branchek,et al.  Characterisation of 5-HT receptors in human coronary arteries by molecular and pharmacological techniques. , 1999, European journal of pharmacology.

[35]  C. White,et al.  Morphologic comparison of atherosclerotic lesions in native coronary arteries and saphenous vein graphs with intracoronary angioscopy in patients with unstable angina. , 1998, American heart journal.

[36]  E J Topol,et al.  Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention. , 1998, Circulation.

[37]  R. Erbel,et al.  Comparison of myocardial perfusion reserve before and after coronary balloon predilatation and after stent implantation in patients with postangioplasty restenosis. , 1996, Circulation.

[38]  J. Maclouf,et al.  Cyclooxygenases-1 and −2 of Endothelial Cells Utilize Exogenous or Endogenous Arachidonic Acid for Transcellular Production of Thromboxane (*) , 1996, The Journal of Biological Chemistry.

[39]  Y. Nishimura,et al.  ENHANCED CONTRACTILE RESPONSES MEDIATED BY DIFFERENT 5‐HT RECEPTOR SUBTYPES IN BASILAR ARTERIES, SUPERIOR MESENTERIC ARTERIES AND THORACIC AORTAS FROM STROKE‐PRONE SPONTANEOUSLY HYPERTENSIVE RATS , 1995, Clinical and experimental pharmacology & physiology. Supplement.

[40]  A. Zeiher,et al.  Tissue endothelin-1 immunoreactivity in the active coronary atherosclerotic plaque. A clue to the mechanism of increased vasoreactivity of the culprit lesion in unstable angina. , 1995, Circulation.

[41]  F. Zijlstra,et al.  Low‐Dose Aspirin Inhibits Platelet‐Induced Contraction of the Human Isolated Coronary Artery: A Role for Additional 5 ‐Hydroxytryptamine Receptor Antagonism Against Coronary Vasospasm? , 1994, Circulation.

[42]  M. Yacoub,et al.  Interaction Between Thromboxane A2 and 5‐Hydroxytryptamine Receptor Subtpes in Human Coronary Arteries , 1993, Circulation.

[43]  W. Ganz,et al.  The thrombolysis in myocardial infarction (TIMI) trial. , 1985, The New England journal of medicine.

[44]  H. S. Mueller,et al.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. , 1985, The New England journal of medicine.